Table 2.
Baseline Clinical, Laboratory, and ART Information of Children on ART in Northeast Ethiopia, 2020
| Variable | Frequency | Percent | |
|---|---|---|---|
| Presence of OIs at base line | Yes | 356 | 73.2 |
| No | 132 | 26.8 | |
| Type of OIs | Pneumonia | 66 | 18.9 |
| Pulmonary tuberculosis | 29 | 8.1 | |
| Upper respiratory tract infection | 45 | 12.6 | |
| Unexplained wasting and stunting | 4 | 1.1 | |
| Diarrhea | 56 | 15.7 | |
| Unexplained Fever | 26 | 7.3 | |
| Herpes zoster | 44 | 12.3 | |
| Oral candidiasis | 25 | 7 | |
| Skin dermatitis | 49 | 13.7 | |
| Other* | 13 | 3.64 | |
| Functional status ≥ 5 years (n=341) | Working | 324 | 95 |
| Ambulatory | 10 | 2.9 | |
| Bed-ridden | 7 | 2.1 | |
| Developmental status < 5 years (n=147) | Appropriate | 121 | 82.3 |
| Delayed | 24 | 16.3 | |
| Regressed | 2 | 1.4 | |
| WHO staging | Stage I | 134 | 27.5 |
| Stage II | 171 | 35 | |
| Stage III | 166 | 34 | |
| Stage IV | 17 | 3.5 | |
| Hemoglobin level | ≥ 10 mg/dl | 431 | 88.3 |
| < 10 mg/dl | 57 | 11.7 | |
| CD4 count | ≥350 cells | 227 | 46.5 |
| < 350 cells | 261 | 53.5 | |
| Eligibility criteria | Clinical (WHO staging) | 50 | 10.2 |
| CD4 count | 235 | 48.2 | |
| Without criteria | 139 | 28.5 | |
| DBS positive | 28 | 5.7 | |
| Both clinical and CD4 count | 36 | 7.4 | |
| Baseline regimen | 4a(d4t-3TC-NVP) | 116 | 23.8 |
| 4b(d4t-3TC-EFV | 51 | 10.5 | |
| 4c(AZT-3TC-NV) | 137 | 28.1 | |
| 4d(AZT-3TC-EFV | 88 | 18 | |
| 1e(TDF-3TC-EFV) | 51 | 10.5 | |
| 1h(ABC-3TC-NVP) | 9 | 1.8 | |
| 1g(ABC-3TC-EFV) | 15 | 3.1 | |
| 4g(ABC-3TC-LPV/r) | 17 | 3.5 | |
| Other (1c,4i,4j) | 4 | 0.8 | |
| Taking prophylaxis | Yes | 452 | 92.6 |
| No | 36 | 7.4 | |
| Type of prophylaxis | CPT | 440 | 96.3 |
| INH | 13 | 2.8 | |
| Both CPTand INH | 4 | 0.9 | |
| Side effects | Yes | 34 | 7 |
| No | 454 | 93 | |
| Type of side effects | Anemia | 16 | 47 |
| Rash | 14 | 41.2 | |
| Eye discharge | 2 | 5.9 | |
| Other** | 2 | 5.9 | |
| Regimen change | Yes | 281 | 57.6 |
| No | 207 | 42.4 | |
| Reason for change | Drug side effects | 34 | 12 |
| New drug availability | 104 | 36.8 | |
| Drug out of stock | 82 | 29 | |
| New tuberculosis | 6 | 2.1 | |
| Virologic failure | 25 | 8.8 | |
| Weight > 25 kg | 32 | 11.3 | |
| Adherence level | Good | 406 | 83.2 |
| Fair | 38 | 7.8 | |
| Poor | 44 | 9 |
Notes: *HIV wasting syndrome, extra pulmonary tuberculosis, parotid enlargement; **fatigue and nausea.